-
-
-
-
-
-
-
Quest Diagnostics (DGX) PT Raised to $245 at BofA Securities
-
-
-
-
-
-
-
Quest Diagnostics launches AI tool to explain lab results
-
-
-
-
-
-
-
Octave Bioscience Forms Strategic Collaboration with Quest Diagnostics to Expand Patient Access to the Octave® Multiple Sclerosis Disease Activity (MSDA) Test Across the U.S.
-
-
-
-
-
-
-
Baird Downgrades Quest Diagnostics (DGX) to Neutral
-
-
-
-
-
-
-
Quest Diagnostics (DGX) Introduces HPV Specimen Self-Collection for Cervical Cancer Screening
-
-
-
-
-
-
-
Quest Diagnostics (DGX) PT Raised to $178 at Mizuho
-
-
-
-
-
-
-
Morgan Stanley Upgrades Quest Diagnostics (DGX) to Overweight
-
427,876 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

